| Role of Wnt/beta-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance |
28 |
| Combined hepatocellular cholangiocarcinoma (cHCC-CC): an update of genetics, molecular biology, and therapeutic interventions |
20 |
| Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date |
15 |
| LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance |
13 |
| Pretreatment neutrophil-lymphocyte ratio: useful prognostic biomarker in hepatocellular carcinoma |
11 |
| Hepatocellular carcinoma: a review of diagnostic challenges for the pathologist |
9 |
| Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives |
8 |
| Genetic Biomarkers For Hepatocellular Carcinoma In The Era Of Precision Medicine |
8 |
| Intermediate stage hepatocellular carcinoma: a summary review |
7 |
| Hepatitis C Antiviral Therapy In Patients With Successfully Treated Hepatocellular Carcinoma: Dancing With Wolves |
5 |
| Weighing the benefits of hepatocellular carcinoma surveillance against potential harms |
4 |
| Status of, and strategies for improving, adherence to HCC screening and surveillance |
4 |
| Update on hepatocellular carcinoma from the 2018 Gastrointestinal Cancer Symposium (ASCO GI) |
4 |
| Liver resection versus radiofrequency ablation for hepatitis B virus-related small hepatocellular carcinoma |
4 |
| Hepatocellular cancer pain: impact and management challenges |
3 |
| Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma |
3 |
| Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria |
3 |
| Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein |
3 |
| Road map for fibrolamellar carcinoma: progress and goals of a diversified approach |
2 |
| Sorafenib plus tegafur-uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study) |
2 |
| Clinical outcomes of rare hepatocellular carcinoma variants compared to pure hepatocellular carcinoma |
2 |
| Prospective Phase II trial of drug-eluting bead chemoembolization for liver transplant candidates with hepatocellular carcinoma and marginal hepatic reserve |
2 |
| Efficacy of loco-regional treatment for hepatocellular carcinoma prior to living donor liver transplantation: a report from a single center in Egypt |
2 |
| Hepatitis C virus-associated hepatocellular carcinoma as a second primary malignancy: exposing an overlooked presentation of liver cancer |
2 |
| Post-translational modifiers of liver kinase B1/serine/threonine kinase 11 in hepatocellular carcinoma |
1 |
| Socioeconomic And Survival Differences Among Minorities With Hepatocellular Carcinoma In Florida |
1 |
| Basic MRI for the liver oncologists and surgeons |
0 |
| Decreased hepatocellular carcinoma tumor burden with the achievement of hepatitis C virus sustained virologic response: unlocking the potential of T-cell-mediated immunosurveillance |
0 |
| Hepatitis B And Hepatitis C Viral Infections And Associated Factors Among Patients With Diabetes Visiting Gondar Referral Teaching Hospital, Northwest Ethiopia: A Comparative Cross-Sectional Study |
0 |
